Background. In this analysis, we examine the incidence and clearance of external genital
human papillomavirus (HPV) infection among heterosexual males aged 16–24 years …

Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age
group in a large US cohort with private insurance to detect potential decreases among …

The prevalence of genital warts (GW) and self-reported human papillomavirus (HPV) as well
as disease-related psychosocial impact among male and female patients aged 18–60 years …

Objectives The aim of the study was to understand which human papillomavirus (HPV) types
are involved in external genital warts (GWs) in a group of Argentinian women in Buenos …

Background The impact of fewer than 3 doses of human papillomavirus (HPV) vaccine on
genital warts is uncertain. Methods Using the Truven Health Analytics Marketscan …

Objectives. To detect decreases in anogenital warts (AGW) among sex and age groups
likely to be affected by human papillomavirus vaccination. Methods. We estimated annual …

Background. We report the first nationally representative prevalence data on genital human
papillomavirus (HPV) in males in the United States, using findings from the National Health …

Methods: Participants 18 to 45 years old who were living in Montreal, Canada, and in a
heterosexual relationship of 6 months or less were randomly assigned to receive the …

Background The quadrivalent human papillomavirus (HPV) vaccine was introduced in the
Portuguese National Immunization Program in October 2008, targeting 13-year-old girls …

Because of the rapid development of genital warts (GW) after infection, monitoring GW
trends may provide early evidence of population-level human papillomavirus (HPV) vaccine …